Seoul Economic Daily EnglishDoubao · 实盘不做把握 5/10不做原因:已被定价
北京时间·🕒 发布 09:35:15(首尔 10:35)·⟳ 抓取 09:55:23 +20m08s·⚡ 决策 10-27 17:48:46 +7h53m·9.8 小时前
Celltrion三季报营收1.5755万亿、营业利润5253亿韩元双创纪录，略超10月12日初步数据
三季报主体内容(营收约1.5万亿、营业利润约5100亿、双纪录、高增长)已于2026-10-12以初步业绩形式公开，本次正式财报仅小幅上修(营收+755亿/+5.0%、营业利润+153亿/+3.0%)，属预期内确认；DART正式披露发生在韩国交易时段，市场已用整个10月27日交易日消化，当前韩股已收盘、无韩股行情源无法核价，明日开盘只能追已反应的价格，风险回报不足。无A股/港/美可交易映射载体。
📄 原文Seoul Economic Daily English↗ 原文
Celltrion Q3 Operating Profit Jumps 74% to 525.3 Billion Won
Celltrion (068270.KS) posted record quarterly revenue and operating profit in the third quarter. The company said on th…
不做 Celltrion（068270.KS）
已price-in且无执行edge：核心三季报双纪录+高增长在10/12初步业绩已公开交易，10/27正式财报仅小幅上修(营业利润+3%)，盘中发布当日已被韩股消化，现收盘；本机无韩股行情源无法核价与设可执行止损，明日开盘只能追已反应价格，风险回报不足。无美/港/A股可交易替代载体。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Celltrion Q3营收/营业利润双创纪录且略超10月12日初步数据，但超预期幅度小(营业利润+3%)、核心增长旧闻已在10/12交易，正式财报盘中发布当日已被消化，韩股收盘且本机无法核价执行，故不做。
消息传播链
- 正式合并财报营收1.5755万亿、营业利润5253亿，较初步数小幅上修；发布于韩国交易时段，当日有完整交易日消化市场反应:本机无韩股行情源，未能核验当日收盘涨跌与成交量
- 韩媒在正式披露当日跟进报道'tops preliminary estimate'，SEDaily英文稿于收盘后到达，无新增大幅超预期
关键理由
- 最终数对初步数上修有限(营业利润+153亿/+3.0%、营收+755亿/+5.0%)，且核心双纪录+高增长在10/12初步业绩已公开并定价，本次为预期内确认而非新预期差
主要风险
- 无韩股行情源，无法量化当日涨幅与是否已充分price-in，明日开盘存在追高/见光死双向风险
- Omlyclo美国铺货、Eydenzelt渠道及ADC管线等叙事若带动后续上修可能使股价续强，但属未量化前瞻，不构成本次短线edge
反向证据
- 做多前查反向 · 来源 stock_quote · 日期 2026-10-27 · 影响 weakens
本机不支持韩国市场行情(仅美股/港股/A股)，无法核验当日涨跌、量能、距高与次日开盘估值，无法设可执行买点与止损
检索:stock_quote 068270.KS 韩股行情 - 做多前查反向 · 来源 web · 日期 2026-10-27 · 影响 weakens
正式数仅较初步数营业利润+153亿(+3.0%)、营收+755亿(+5.0%)，属小幅确认，非新大幅超预期；核心增长10/12已交易
检索:Celltrion 3Q preliminary October 12 vs final beat magnitude 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例缺失叠加无韩股行情源，压低置信度并直接导向AVOID，而非凭感觉给追多
方向:未对Celltrion及韩股大型生物科技'初步业绩→正式财报小幅上修'取得可锚首发、同相位对齐样本，不用跨市场幅度数字硬套
涨幅量级:不足：无干净同市场同机制先例可校准次日开盘幅度，且小幅beat+旧闻的交易结构本身edge有限
形态:未能用先例证实续涨或见光死；仅凭机制(盘中正式财报+小幅上修+旧闻)判定price-in风险高
工具执行结果 · 成功 2 · 降级 1 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 315 ms
{"result": "search_processed_events:agent query=`celltrion 068270 q3 record operating profit revenue preliminary results | celltrion third quarter 2026 earnings remsima zymfentra omlyclo | 셀트리온 3분기 실적 영업이익 5253억 잠정실적`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 67.5/72 小时、3418 条本臂决策(完整)，返回 3 条候选。\n• 10-26 07:22 UTC(北京 - stock_quote 降级 stock_tools HTTP · 11 ms
本机没有该市场的行情源(数据中台只覆盖美股、港股、A股)。不能用本工具核验价格和可执行条件；如需交易请改选美/港/A股上的可交易载体，否则在 reason 里注明无法定价，不得编造价位。 - web_search 成功 doubao_search · 1,452 ms
豆包搜索结果（原始查询:Celltrion 3Q26 earnings record operating profit 525.3 billion preliminary beat shares；API SearchType:web）
原文全文
展开原文 · 2,239 字
Celltrion (068270.KS) posted record quarterly revenue and operating profit in the third quarter.
The company said on the 27th that consolidated revenue reached 1.5755 trillion won ($1.1 billion) and operating profit 525.3 billion won ($367 million), up 53.1% and 74.3% respectively from a year earlier. Its operating margin rose 4.0 percentage points to 33.3%. Both figures came in above the preliminary results released on Oct. 12, with revenue 75.5 billion won higher and operating profit 15.3 billion won higher.
Newer, higher-margin products drove the gains. Revenue from these products rose about 74% from a year earlier to 905.8 billion won, approaching the 1 trillion won mark. They accounted for 67% of biologics revenue, up 13 percentage points from a year earlier and 2 percentage points from the previous quarter. The company expects that share to reach 70% by the end of the year.
Flagship products also kept growing. Combined third-quarter revenue from Remsima SC, an autoimmune treatment containing infliximab, and Zymfentra, its U.S. brand name, rose 19% from a year earlier to 254.2 billion won. Cumulative revenue through the third quarter reached 710.4 billion won, putting 1 trillion won for the full year within reach. Yuflyma revenue rose 27% to 183.2 billion won.
Omlyclo, an allergy treatment, generated cumulative revenue of 320.5 billion won through the third quarter, up 542.3% from 49.9 billion won a year earlier. Already sold in 26 European countries, Omlyclo launched in the U.S. market earlier this month. The company plans to expand prescriptions by drawing on the product's track record in Europe and its direct sales network in the United States. Eydenzelt, an ophthalmic treatment, recently signed an exclusive supply agreement with a large U.S. health care company, securing sales channels that span insurance markets and hospital supply networks.
"We plan to continue developing new drugs, including antibody-drug conjugates, using cash generated from our existing biosimilar business," a Celltrion official said. "Having achieved record operating profit even after accounting for research and development spending, we will secure both profitability in our existing business and future growth drivers."
The company said on the 27th that consolidated revenue reached 1.5755 trillion won ($1.1 billion) and operating profit 525.3 billion won ($367 million), up 53.1% and 74.3% respectively from a year earlier. Its operating margin rose 4.0 percentage points to 33.3%. Both figures came in above the preliminary results released on Oct. 12, with revenue 75.5 billion won higher and operating profit 15.3 billion won higher.
Newer, higher-margin products drove the gains. Revenue from these products rose about 74% from a year earlier to 905.8 billion won, approaching the 1 trillion won mark. They accounted for 67% of biologics revenue, up 13 percentage points from a year earlier and 2 percentage points from the previous quarter. The company expects that share to reach 70% by the end of the year.
Flagship products also kept growing. Combined third-quarter revenue from Remsima SC, an autoimmune treatment containing infliximab, and Zymfentra, its U.S. brand name, rose 19% from a year earlier to 254.2 billion won. Cumulative revenue through the third quarter reached 710.4 billion won, putting 1 trillion won for the full year within reach. Yuflyma revenue rose 27% to 183.2 billion won.
Omlyclo, an allergy treatment, generated cumulative revenue of 320.5 billion won through the third quarter, up 542.3% from 49.9 billion won a year earlier. Already sold in 26 European countries, Omlyclo launched in the U.S. market earlier this month. The company plans to expand prescriptions by drawing on the product's track record in Europe and its direct sales network in the United States. Eydenzelt, an ophthalmic treatment, recently signed an exclusive supply agreement with a large U.S. health care company, securing sales channels that span insurance markets and hospital supply networks.
"We plan to continue developing new drugs, including antibody-drug conjugates, using cash generated from our existing biosimilar business," a Celltrion official said. "Having achieved record operating profit even after accounting for research and development spending, we will secure both profitability in our existing business and future growth drivers."
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
05f5004492· 2026-10-27 17:48 · doubao / doubao-seed-evolving-latest-version · 策略包b7b4acf827b8当前